<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01143948</url>
  </required_header>
  <id_info>
    <org_study_id>LC-T2D</org_study_id>
    <nct_id>NCT01143948</nct_id>
  </id_info>
  <brief_title>Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial</brief_title>
  <acronym>VIRDICT</acronym>
  <official_title>Insulin Therapy in the Inpatient Management of Cirrhotic Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver disease is an important cause of death in type 2 diabetes. In the population-based
      Verona Diabetes Study cirrhosis was the fourth leading cause of death and accounted for 4.4%
      of diabetes-related deaths. In another prospective cohort study , cirrhosis accounted for
      12.5% of deaths in patients with diabetes. In Egypt hepatitis C virus the commonest of
      cirrhosis here has a prevalence of 9.8% in the population with the greatest burden over
      national health care bills. Patients with cirrhosis &amp; type 2 diabetes mellitus are always
      showing up in all hospital wards without a clear consensus of best management of their
      hyperglycemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Best management of hyperglycemia in non-intensive care unit Cirrhotic patients with type 2
      diabetes by different insulin regimens either sliding scale regular insulin or basal bolus
      insulin using NPH &amp; regular insulin or Glargine &amp; Glulisine.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">May 2011</completion_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>optimal glycemic control in inpatient cirrhotics</measure>
    <time_frame>3-7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypoglycemic episodes</measure>
    <time_frame>3-7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>15 patient sliding scale regular insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>15 patient BBI NPH plus regular insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>15 patients BBI Glargine plus Glulisine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glargine &amp; Glulisine</intervention_name>
    <description>Basal Glargine &amp; bolus Glulisine</description>
    <arm_group_label>15 patients BBI Glargine plus Glulisine</arm_group_label>
    <other_name>lantus</other_name>
    <other_name>apidra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regular insulin</intervention_name>
    <description>Sliding scale regular insulin</description>
    <arm_group_label>15 patient sliding scale regular insulin</arm_group_label>
    <other_name>actrapid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPH &amp; regular insulin</intervention_name>
    <description>Basal NPH &amp; bolus regular insulin</description>
    <arm_group_label>15 patient BBI NPH plus regular insulin</arm_group_label>
    <other_name>mixtard</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hospitalized type 2 Diabetes Mellitus with liver cirrhosis

          -  Entry blood glucose (fasting or random) greater than 180 mg%

        Exclusion Criteria:

          -  Type 1 Diabetes Mellitus

          -  Pregnancy

          -  Steroids: prednisone greater than 7.5mg/day or equivalent

          -  Serum Creatinine &gt; 3 mg/dl

          -  Patients in intensive care units.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ibtisam Z Eissa, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary N Rizk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo Univerity</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmad A Khairy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mostafa M Alfishawy, MB BCh</last_name>
    <phone>0111183371</phone>
    <email>mostafa.alfishawy@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Internal medicine hospital ,Cairo University</name>
      <address>
        <city>Cairo</city>
        <zip>11956</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Balkau B, Eschwège E, Ducimetière P, Richard JL, Warnet JM. The high risk of death by alcohol related diseases in subjects diagnosed as diabetic and impaired glucose tolerant: the Paris Prospective Study after 15 years of follow-up. J Clin Epidemiol. 1991;44(6):465-74.</citation>
    <PMID>2037851</PMID>
  </reference>
  <reference>
    <citation>de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care. 1999 May;22(5):756-61.</citation>
    <PMID>10332677</PMID>
  </reference>
  <results_reference>
    <citation>Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007 Mar;30(3):734-43. Review.</citation>
    <PMID>17327353</PMID>
  </results_reference>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2010</study_first_submitted>
  <study_first_submitted_qc>June 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2010</study_first_posted>
  <last_update_submitted>June 14, 2010</last_update_submitted>
  <last_update_submitted_qc>June 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Internal Medicine Department</name_title>
    <organization>Cairo University</organization>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Insulin</keyword>
  <keyword>Inpatient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

